key: cord-0321791-uk4kun8f authors: Singsuksawat, Ekapot; Onnome, Suppachoke; Posiri, Pratsaneeyaporn; Suphatrakul, Amporn; Srisuk, Nittaya; Nantachokchawapan, Rapirat; Praneechit, Hansa; Sae-kow, Chutimon; Chidpratum, Pala; Hongeng, Suradej; Avirutnan, Panisadee; Duangjinda, Thaneeya; Siridechadilok, Bunpote title: Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by virus-like particle date: 2020-05-17 journal: bioRxiv DOI: 10.1101/2020.05.17.100388 sha: 51c91ed9dc04745b46f7575671bbb361bbb09bf7 doc_id: 321791 cord_uid: uk4kun8f With sequencing as a standard frontline protocol to identify emerging viruses such zika virus and SARS-CoV2, direct utilization of sequence data to program antivirals against the viruses could accelerate drug development to treat their infections. CRISPR-Cas effectors are promising candidates that could be programmed to inactivate viral genetic material based on sequence data but several challenges such as delivery and design of effective crRNA need to be addressed to realize practical use. Here, we showed that virus-like particle (VLP) could deliver PspCas13b-crRNA ribonucleoprotein (RNP) in nanomolar range to efficiently suppress dengue virus infection in primary human target cells. Shortening spacer length could significantly enhance RNA-targeting efficiency of PspCas13b in mammalian cells compared to the natural length of 30 nucleotides without compromising multiplex targeting by a crRNA array. Our results demonstrate the potentials of applying PspCas13b RNP to suppress RNA virus infection, with implications in targeting host RNA as well. With sequencing as a standard frontline protocol to identify emerging viruses such 25 zika virus and SARS-CoV2, direct utilization of sequence data to program antivirals 26 against the viruses could accelerate drug development to treat their infections. 27 CRISPR-Cas effectors are promising candidates that could be programmed to 28 inactivate viral genetic material based on sequence data but several challenges such 29 as delivery and design of effective crRNA need to be addressed to realize practical 30 use. Here, we showed that virus-like particle (VLP) could deliver PspCas13b-crRNA To characterize the antiviral activity of CRISPR-Cas13 against flavivirus, we first 61 established a stable BHK21 clone (BHK21-Cas13b) that could be induced with 62 doxycycline to express PspCas13b using lentivirus (Supplementary Figure 1a) . 63 Type I-interferon defective BHK21 cell line was chosen as the host cell for its ability 64 to support high level of dengue virus (DENV) and zika virus (ZIKV) replication (Liu et 65 al., 2006) , providing a robust platform to evaluate viral suppression activity. 66 Inducible expression system appeared to provide the stability of Cas13b cassette in 67 BHK21 as we were not able to maintain PspCas13b expression under a constitutive for subsequent experiments (Supplementary Figure 1b) . Though Figure 1b) . The suppression of DENV2-mCherry by mCh3 crRNA 80 was specific as other reporter DENV2 could not be suppressed by the crRNA in both 81 single-virus infection and co-infection settings (Supplementary Figures 1c-d) . 82 Using BHK21-Cas13b, we individually tested 51 crRNAs against the targets on 83 DENV2 reporter viruses, DENV2-16681 (NS5 gene), and ZIKV-SV0010 (NS2A 84 gene) (Supplementary Table 1 (Pewkliang et al., 2018) ). The 118 VLP was effective at delivering YFP to these cells (Supplementary Figure 1b) . We 119 found that the VSV-G pseudotyped VLP preferentially target CD14 + monocytes in 120 (Supplementary Figures 3a-b) . Nevertheless, the 142 knock-down activity of two crRNAs (mAmet1 and 8681) were aggravated by 22-nt 143 spacer (Supplementary Figures 3a-b) . We selected three pairs of 30-nt vs. 22-nt crRNAs for testing by VLP delivery in BHK21 cells. The knock-down enhancement 145 was recapitulated with Cas13b RNP delivery by VLP for 22-nt vs. 30-nt mCh3 146 crRNAs (Figure 3c) . In contrast to the results in BHK21-Cas13b, the 22-nt mAmet-1 147 crRNA could knock down DENV2-mAmet with much less PspCas13b than its 30-nt 148 counterpart (Figure 3c) . The dose-response curves indicated that the 22-nt mCh3 149 and mAmet1 crRNAs needed 15-20 folds less of PspCas13b than 30-nt crRNAs to 150 achieve the same level of virus suppression (Figure 2c) The isolated CD14 + monocytes were cultured in R10 supplemented with 5% HI-316 human AB serum to allow differentiation into macrophages (Brugger et al., 1991) . crRNA array with three crRNAs, 2x = crRNA array with two crRNAs, 1x = singlet of dengue virus infection Macrophage colony-stimulating factor 585 is required for human monocyte survival and acts as a cofactor for their terminal 586 differentiation to macrophages in vitro Detection of Zika Virus Infection in Thailand A versatile viral 594 system for expression and depletion of proteins in mammalian cells RNA editing with CRISPR-Cas13 Phenotyping of peripheral blood mononuclear 601 cells during acute dengue illness demonstrates infection and increased activation 602 of monocytes in severe cases compared to classic dengue fever Programmable Inhibition and Detection of RNA Viruses Using Multiplexed and portable nucleic acid detection platform with Cas13 dengue virus in naturally infected human tissues, by immunohistochemistry and 616 in situ hybridization Protein delivery using engineered virus-like particles Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors A 625 single amino acid substitution in the West Nile virus nonstructural protein NS2A 626 disables its ability to inhibit alpha/beta interferon induction and attenuates virus 627 virulence in mice CRISPR-Cas13d mediates robust RNA 630 virus interference in plants Genome editing in primary cells and in vivo using viral-derived Nanoblades 636 loaded with Cas9-sgRNA ribonucleoproteins Lentiviral Vectors for the 639 Treatment and Prevention of Cystic Fibrosis Lung Disease Rewiring cellular 642 networks by members of the Flaviviridae family A novel immortalized hepatocyte-like cell 647 line (imHC) supports in vitro liver stage development of the human malarial 648 parasite Plasmodium vivax Dengue reporter viruses reveal viral dynamics in interferon 651 receptor-deficient mice and sensitivity to interferon effectors in vitro Visualization of retroviral replication in living cells reveals budding into 657 multivesicular bodies Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and 662 Lentivirus-delivered stable gene silencing by RNAi in primary 664 cells Multi-color fluorescent reporter dengue 667 viruses with improved stability for analysis of a multi-virus infection Massively parallel Cas13 screens reveal principles for guide RNA 671 design Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector 674 Positively Modulated by a WYL-Domain-Containing Accessory Protein Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13 Targeting of multiple reporter DENV2 with the crRNA array in single-virus 716 (left bar plot) and three-virus (right bar plot) infections. HAK = crRNA array shown in 717 a). The measurements for crRNA arrays were done in triplicate. The rest were done 718 in duplicate. d) Dose-response curves of multiplex VLP-Cas13b RNP generated with 719 a crRNA array Supplementary Figure 1: Flaviviral suppression with CRISPR-Cas13b by 725 inducible expression in BHK21. a) Diagram describing the inducible expression 726 system that controlled the expression of The top panel is the bright-field image of BHK21 expressing various form 729 of PspCas13b. The middle panel is the same views of the top panel but with anti-HA 730 signal representing the location of PspCas13b DENV2-mCherry intensity in BHK21 with crRNAs and different forms of PspCas13b Viral suppression for each reporter 734 DENV2 is shown as mean-fluorescent intensity (MFI) histograms from flow-735 cytometry measurement of infected cells. d) Specific viral suppression of reporter 736 DENV2 by mCh3 crRNA in co-infection setting. Viral suppression for each reporter 737 DENV2 is shown as heat-map scatter plot from flow-cytometry measurement of 738 infected cells. e) Summary bar plot of viral suppression activities of 51 crRNAs 739 individually tested. Viral suppression is presented as a mean of knock-down ratio 740 (KD ratio) calculated from the ratio of MFI in BHK21-Cas13b with experimental 741 crRNA relative to the MFI in BHK21-Cas13b with nontarget crRNA from duplicate 742 measurements (error bar = standard deviation) The left bar 746 plot compare infectious titers of DENV2-16681 between BHK21-Cas13b with 8681 747 crRNA and BHK21-Cas13b with mCh3 crRNA (nontarget control) at 48 hours post 748 infection (hpi) and 72 hpi (error bar = standard deviation). The measurements were 749 done in duplicate Supplementary Figure 2: VLP delivery of protein cargo into human primary 753 target cells. a) Diagram showing the generation of VLP for PspCas13b RNP 754 delivery (adapted from (Mangeot et al., 2019)). b) Delivery of YFP into various 755 mammalian cells. The figure show the results of transducing BHK21, hDC, macrophages, iMHC, and CD14+ monocytes with VLP-YFP from fluorescent 757 microscopy (bright-field images and fluorescent images) and percent transduction 758 measured by flow cytometry. c) Flow cytometry analysis of YFP delivery by VLP Supplementary Figure 3: The comparison of virus suppression activity 762 between 22-nt and 30-nt crRNAs and in vitro cleavage. a) crRNA set for 763 targeting fluorescent reporter genes. b) crRNA set for targeting NS5 gene of DENV2-16681. c) In vitro cleavage of mCherry RNA by PspCas13b + 22-nt mCh3